Evidence map›Paper›PMID 38155924›Full record

ReviewFrontiers in bioengineering and biotechnology2023

Strategies to improve the therapeutic efficacy of mesenchymal stem cell-derived extracellular vesicle (MSC-EV): a promising cell-free therapy for liver disease.

Lijuan Zheng, Hui Gong, Jing Zhang, Linna Guo, Zhuofan Zhai, Shuang Xia, Zhiyu Hu, Jing Chang, Yizhu Jiang, Xinran Huang and 3 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in bioengineering and biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. [Exploring the protective effects and mechanisms of HYX1-derived exosomes on acute liver failure based on disulfidptosis signaling].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Lijuan Zheng *Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
Hui Gong *Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
Jing ZhangXiangya School of Pharmaceutical Sciences, Central South University, Changsha, China.
Linna GuoDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
Zhuofan ZhaiXiangya School of Medicine, Central South University, Changsha, China.
Shuang XiaDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
Zhiyu HuDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
Jing ChangXiangya School of Medicine, Central South University, Changsha, China.
Yizhu JiangXiangya School of Medicine, Central South University, Changsha, China.
Xinran HuangXiangya School of Medicine, Central South University, Changsha, China.
Jingyi GeXiangya School of Medicine, Central South University, Changsha, China.
Bikui ZhangDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
Miao YanDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
Central South University · CNSecond Xiangya Hospital of Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver disease has emerged as a significant worldwide health challenge due to its diverse causative factors and therapeutic complexities. The majority of liver diseases ultimately progress to end-stage liver disease and liver transplantation remains the only effective therapy with the limitations of donor organ shortage, lifelong immunosuppressants and expensive treatment costs. Numerous pre-clinical studies have revealed that extracellular vesicles released by mesenchymal stem cells (MSC-EV) exhibited considerable potential in treating liver diseases. Although natural MSC-EV has many potential advantages, some characteristics of MSC-EV, such as heterogeneity, uneven therapeutic effect, and rapid clearance

Indexed as

bioengineeringextracellular vesicleliver diseasemesenchymal stem celltherapeutic efficacy

Identifiers

PMID38155924
PMCPMC10753838
OpenAlexW4389684234

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.